A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis

Alexander C. Hyatt, Bradley E. Chipps, Karen M. Kumor, E. David Mellits, Paul S. Lietman, Beryl J. Rosenstein

Research output: Contribution to journalArticle

Abstract

A double-blind controlled trial of anti-Pseudomonas chemotherapy was carried out in 24 exacerbations of pulmonary disease in patients with cystic fibrosis. Fifteen exacerbations were treated with oxacillin plus sisomicin and carbenicillin (treatment group); nine were treated with oxacillin alone (control group). The planned length of treatment was 14 days. The difference between the failure rate in the treatment group (3/15) and the control group (7/9) was statistically significant (P<0.015). The difference in improvement of forced expiratory volume in 1 second was also significant (P<0.025). At the end of the study, Pseudomonas aeruginosa was still present in the sputum of all nine patients in the control group, but was not isolated from six of the 15 patients in the treatment group. The data suggest a beneficial role for anti-Pseudomonas chemotherapy in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)307-311
Number of pages5
JournalThe Journal of pediatrics
Volume99
Issue number2
DOIs
StatePublished - Aug 1981

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis'. Together they form a unique fingerprint.

  • Cite this